LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group director Robert Bessler reported open-market sales of LifeStance Health Group, Inc. common stock through entities associated with him. Shama LLC and Vitthal LLC each sold 37,500 shares at a weighted average price of $8.55 per share, in transactions ranging from $8.40 to $8.89. After these sales, Shama LLC held 1,353,746 shares and Vitthal LLC held 1,236,948 shares. Bessler also reported 57,619 shares held directly and 36,363 shares held by Alpine Glow Capital. Footnotes state that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
Summit Partners and affiliated funds reported shared beneficial ownership of LifeStance Health Group common stock. Summit Partners, L.P. has 29,209,776 shares with shared voting and dispositive power, representing 7.49% of the class. The filing cites 389,783,210 shares outstanding as of February 17, 2026.
The Schedule 13G/A lists related Summit entities (including Growth Equity Fund IX‑A and IX‑B) with shared holdings of 17,886,858 and 11,168,308 shares respectively and explains the fund/committee voting structure and delegations.
LifeStance Health Group, Inc. is offering for resale 35,000,000 shares of common stock by selling stockholders; the Company is not selling any shares hereunder and will receive no proceeds from those sales. Subject to the closing of the offering, the Company intends to purchase 6,000,000 shares from the underwriter at the public offering price and retire them. The repurchase is contingent on the offering closing. Shares outstanding were 387,834,432 as of April 29, 2026. The underwriter is J.P. Morgan, the public offering price is $8.15 per share and the underwriting discount is $0.13 per share. The underwriter expects to deliver the shares on or about May 12, 2026.
35,000,000 shares of common stock are being registered for resale by identified selling stockholders of LifeStance Health Group, Inc. The Company is not selling any shares and will not receive proceeds from the selling stockholders' sales.
Subject to the offering closing, LifeStance intends to purchase 6,000,000 of the offered shares from the underwriter at the same per-share price paid by the underwriter and retire those repurchased shares. Shares outstanding were 387,834,432 as of April 29, 2026. The prospectus supplement states the Company estimates offering expenses of approximately $500,000 and quotes a last reported Nasdaq sale price of $7.36 on May 6, 2026.
35,000,000 shares of common stock are being registered for resale by identified selling stockholders of LifeStance Health Group, Inc. The Company is not selling any shares and will not receive proceeds from the selling stockholders' sales.
Subject to the offering closing, LifeStance intends to purchase 6,000,000 of the offered shares from the underwriter at the same per-share price paid by the underwriter and retire those repurchased shares. Shares outstanding were 387,834,432 as of April 29, 2026. The prospectus supplement states the Company estimates offering expenses of approximately $500,000 and quotes a last reported Nasdaq sale price of $7.36 on May 6, 2026.
35,000,000 shares of common stock are being registered for resale by identified selling stockholders of LifeStance Health Group, Inc. The Company is not selling any shares and will not receive proceeds from the selling stockholders' sales.
Subject to the offering closing, LifeStance intends to purchase 6,000,000 of the offered shares from the underwriter at the same per-share price paid by the underwriter and retire those repurchased shares. Shares outstanding were 387,834,432 as of April 29, 2026. The prospectus supplement states the Company estimates offering expenses of approximately $500,000 and quotes a last reported Nasdaq sale price of $7.36 on May 6, 2026.
LifeStance Health (LFST) filed a Form 144 reporting proposed sales of 75,000 shares of Common Stock, with an aggregate value listed as $641,580.00, dated 05/07/2026.
The filing also records recent dispositions: 5,101 shares on 04/21/2026 for $35,749.48, 7,752 shares on 04/23/2026 for $54,267.10, and 62,147 shares on 04/24/2026 for $438,074.20. The excerpt shows two prior private placement transfers dated 06/01/2017 of 37,500 shares each to Vitthal LLC and Shama LLC.
LifeStance Health (LFST) filed a Form 144 reporting proposed sales of 75,000 shares of Common Stock, with an aggregate value listed as $641,580.00, dated 05/07/2026.
The filing also records recent dispositions: 5,101 shares on 04/21/2026 for $35,749.48, 7,752 shares on 04/23/2026 for $54,267.10, and 62,147 shares on 04/24/2026 for $438,074.20. The excerpt shows two prior private placement transfers dated 06/01/2017 of 37,500 shares each to Vitthal LLC and Shama LLC.
LifeStance Health (LFST) filed a Form 144 reporting proposed sales of 75,000 shares of Common Stock, with an aggregate value listed as $641,580.00, dated 05/07/2026.
The filing also records recent dispositions: 5,101 shares on 04/21/2026 for $35,749.48, 7,752 shares on 04/23/2026 for $54,267.10, and 62,147 shares on 04/24/2026 for $438,074.20. The excerpt shows two prior private placement transfers dated 06/01/2017 of 37,500 shares each to Vitthal LLC and Shama LLC.
LifeStance Health Group reported strong Q1 performance, with total revenue rising 21% to $403,476, driven by higher patient service revenue from a larger clinician base and more visits. Income from operations increased to $22,284, and net income improved sharply to $14,243, or $0.04 per diluted share.
Adjusted EBITDA reached $51,110, supported by 2.5 million patient visits and 8,349 employed clinicians as of March 31, 2026. The company generated $33,109 of operating cash flow, repurchased 7,000 shares for $49,107, and ended the quarter with $194,797 in cash. Previously identified material weaknesses in internal control over financial reporting remain unresolved, so disclosure controls are still not effective.
LifeStance Health Group reported strong Q1 performance, with total revenue rising 21% to $403,476, driven by higher patient service revenue from a larger clinician base and more visits. Income from operations increased to $22,284, and net income improved sharply to $14,243, or $0.04 per diluted share.
Adjusted EBITDA reached $51,110, supported by 2.5 million patient visits and 8,349 employed clinicians as of March 31, 2026. The company generated $33,109 of operating cash flow, repurchased 7,000 shares for $49,107, and ended the quarter with $194,797 in cash. Previously identified material weaknesses in internal control over financial reporting remain unresolved, so disclosure controls are still not effective.
LifeStance Health Group reported strong Q1 performance, with total revenue rising 21% to $403,476, driven by higher patient service revenue from a larger clinician base and more visits. Income from operations increased to $22,284, and net income improved sharply to $14,243, or $0.04 per diluted share.
Adjusted EBITDA reached $51,110, supported by 2.5 million patient visits and 8,349 employed clinicians as of March 31, 2026. The company generated $33,109 of operating cash flow, repurchased 7,000 shares for $49,107, and ended the quarter with $194,797 in cash. Previously identified material weaknesses in internal control over financial reporting remain unresolved, so disclosure controls are still not effective.
LifeStance Health Group reported strong first quarter 2026 results driven by higher visit volumes and clinician growth. Revenue rose 21% to $403.5 million, with visit volumes up 18% to 2.5 million and the clinician base up 11% to 8,349. Net income increased to $14.2 million from $0.7 million, and Adjusted EBITDA grew 48% to $51.1 million, or 12.7% of revenue. Center Margin rose 24% to $135.9 million, or 33.7% of revenue. The company generated $33.1 million of operating cash flow and $22.3 million of free cash flow, ending the quarter with $194.8 million in cash and $262.5 million of net long‑term debt. Reflecting this momentum, LifeStance raised its full‑year 2026 guidance for revenue, Center Margin, and Adjusted EBITDA.
LIFESTANCE HEALTH GROUP INC files an Amendment No. 9 to Schedule 13G/A reporting that FMR LLC beneficially owns 58,467,479.69 shares of Common Stock, representing 15.0% of the class as reported. The filing lists sole voting and dispositive power figures and references an attached 13d-1(k) agreement in Exhibit 99 and a power of attorney authorizing the signature. The issuer address is provided as 4800 N. Scottsdale Road, Suite 2500, Scottsdale, AZ.
LifeStance Health Group, Inc. director Robert Bessler reported open-market sales of LifeStance common stock through entities he is associated with. On April 24, Shama LLC sold 31,074 shares and Vitthal LLC sold 31,073 shares at a reported price of $7.05 per share. On April 23, Shama LLC and Vitthal LLC each sold 3,876 shares at a reported price of $7.00 per share.
After these transactions, reported indirect holdings included 1,391,246 shares through Shama LLC, 1,274,448 shares through Vitthal LLC and 36,363 shares held of record by Alpine Glow Capital, plus 57,619 shares held directly. The footnotes state that Bessler disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
LFST submitted a Form 144 notice for proposed sales of Common Stock by affiliated holders. The filing lists 438,074.20 (unit shown) and identifies specific transfers originating from private placements dated 06/01/2017 to Vitthal and Shama entities. The filing also reports actual sales by Robert Bessler of 5,101 and 7,752 shares on 04/21/2026 and 04/23/2026, respectively.